In this multicenter , randomized , double-blind , placebo-controlled , phase 3 study , we assessed the efficacy and safety of idelalisib , an oral inhibitor of the delta isoform of phosphatidylinositol 3-kinase , in combination with rituximab versus rituximab plus placebo .